Science
Mechanism of Action
As a systemic lipid-regulating agent, Gemfibrozil primarily functions by activating peroxisome proliferator-activated receptor-alpha (PPAR-α), a nuclear receptor crucial for lipid metabolism gene regulation. This activation enhances lipoprotein lipase (LPL) activity, leading to the breakdown of triglycerides in VLDL and chylomicrons. It also reduces hepatic triglyceride production by inhibiting peripheral lipolysis and decreasing the liver's uptake of free fatty acids. Furthermore, it impedes the synthesis and accelerates the clearance of VLDL carrier apolipoprotein B, thereby diminishing VLDL production. These systemic actions collectively decrease serum triglycerides and VLDL cholesterol while increasing HDL cholesterol; however, no specific topical mechanism of action for skin has been identified.
Research
Clinical Evidence
Insufficient-data confidenceN/A
Key findings
- 01 Oral administration (1200 mg/day) in patients with primary familial endogenous hypertriglyceridemia significantly increased plasma HDL cholesterol by 36%, apolipoprotein AI by 29%, and apolipoprotein AII by 38%, alongside a 54% decrease in plasma triglycerides.
- 02 Oral administration (600 mg twice daily) markedly reduced serum triglycerides and moderately lowered total serum cholesterol levels in a multicenter study of 427 patients over durations up to 13 months.
- 03 Oral administration (dosage unspecified, for patients on acitretin 0.25-0.75 mg/kg) reduced serum triglycerides and slightly decreased total cholesterol levels in patients with hyperlipidemia unresponsive to diet and acitretin dose reductions.
Transparency
Dusting Analysis
Gemfibrozil is an FDA-approved prescription drug, not a cosmetic ingredient. Therefore, the concept of 'dusting' or its use as a common cosmetic component does not apply.
The Formula
Formulation
Stability
Gemfibrozil is a stable white solid with a pKa of 4.5. It exhibits poor water solubility (0.0019% in water and acid), though its solubility in dilute base exceeds 1%. For aqueous solutions, it can be pre-dissolved in ethanol and then diluted with the aqueous buffer (e.g., approximately 0.5 mg/ml in a 1:1 ethanol:PBS solution at pH 7.2). It is readily soluble in organic solvents such as ethanol, DMSO, and DMF. Nano-formulations are actively researched to enhance its solubility and bioavailability for pharmaceutical purposes.
Conflicts
- simvastatin
- repaglinide
- dasabuvir
- colchicine
- warfarin
- OATP1B1 substrates
Safety
Safety Profile
Gemfibrozil is a prescription drug with no specific safety assessments for cosmetic application by CIR or SCCS. As an oral medication, common side effects include gastrointestinal issues, while more serious adverse effects can involve peripheral neuropathy, myopathy, and rhabdomyolysis. It is contraindicated in conditions like hepatic or severe renal dysfunction and gallbladder issues. Animal studies indicate a slight increase in certain tumors and potential impairment of fertility. It is listed under California Proposition 65 due to its potential to cause cancer and reproductive toxicity in both males and females.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Gemfibrozil is a prescription medication with no established topical skin benefits and significant systemic safety concerns, making it unsuitable and potentially hazardous for cosmetic applications.
Related
Similar Ingredients
Finding similar ingredients…